ArticleBiological trace element research2026
Lycopene Attenuates Hexavalent Chromium-Induced Kidney Injury By Modulating PINK1/Parkin-Mediated Mitophagy.
Article in Biological trace element research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mitochondrial-targeted actions of lycopene: evidence, mechanisms and future directions.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Hexavalent chromium [Cr(VI)] is a well-established environmental nephrotoxicant that induces renal injury. Lycopene (LYC), one of the most potent naturally occurring antioxidants found in plants, has demonstrated protective effects against various forms of oxidative damage; however, its therapeutic role and underlying mechanisms in Cr(VI)-induced nephrotoxicity remain unclear. In this study, eighty female SPF-grade ICR mice were randomly assigned to four groups: control (Con), LYC, Cr(VI), and LYC + Cr(VI), and treated for 28 days. The results demonstrated that LYC significantly alleviated Cr(VI)-induced renal dysfunction and structural damage. Cr(VI) exposure markedly increased malondialdehyde (MDA) and hydrogen peroxide (H₂O₂) levels while suppressing antioxidant enzyme activities, including catalase (CAT), glutathione peroxidase (GSH-Px), and total superoxide dismutase (T-SOD). In contrast, LYC supplementation effectively restored antioxidant capacity and activated the Nuclear factor-erythroid 2-related factor 2(Nrf2) signaling pathway. Moreover, LYC mitigated Cr(VI)-induced mitochondrial dysfunction by suppressing excessive activation of mitochondrial fission-related proteins (Fis1, Drp1, and MFF) and PINK1/Parkin-mediated mitophagy. Notably, LYC co-treatment enhanced the expression of key mitochondrial biogenesis regulators, including Sirt1 and PGC-1α, in renal tissue. Collectively, these findings indicate that LYC protects against Cr(VI)-induced kidney injury, at least in part, by regulating mitochondrial biogenesis, mitochondrial dynamics, mitophagy, and the Nrf2 antioxidant signaling pathway.
Indexed as
Identifiers
42091805What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.